Estimated Time to Complete Activity: 30 minutes
More than 192,000 new breast cancer diagnoses are expected in 2009, making breast cancer the most common cancer among women in the United States. While chemotherapy remains a mainstay of treatment, its use is associated with significant toxicities, and development of resistance to many chemotherapeutic agents is common. Taxanes and anthracyclines have been found to be active and are used to treat all stages of breast cancer; however, resistance to or toxicities from these drugs may prevent their use in the metastatic setting, prompting the need for additional therapies. New therapies that exploit novel therapeutic targets are being tested with success in patients with metastatic breast cancer (MBC). To provide the best possible therapy for their patients with MBC, healthcare professionals must be aware of the risks and benefits of potential therapies. At the conclusion of this activity, participants will be able to compare the safety and efficacy of novel therapies for patients with MBC, based on the latest data from clinical trials.
This activity is intended for medical oncologists, physician assistants, and other healthcare professionals involved in the care of patients with breast cancer.
Upon completion of this activity, participants will be able to
This activity requires that your computer be configured to access the Internet. A high-speed Internet connection may be required to listen to large files. The podcast will be available on iTunes® and www.thecbce.com. The podcast will also be a featured program on the CBCE CME app, which may be downloaded from the Apple® App Store for use on the iPhone® or iPod touch®.
This activity can be accessed using an iPhone® or iPod touch® and will be a featured program on the CBCE CME app, which may be downloaded from the Apple® App Store.
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The CBCE designates this session for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity. Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.
Successful completion of this activity includes the following:
Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest and form.
The CBCE gratefully acknowledges the educational grant provided by sanofi-aventis.
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or sanofi-aventis. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference.
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education. The following faculty have reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process: Clifford A. Hudis, MD Consultant Data and Safety Monitoring Board Genentech, Inc. Grant/Research Support Onyx Pharmaceuticals, Inc. The following faculty declared they have no financial relationships that require disclosure: Edith A. Perez, MD
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.
The CBCE staff have declared they have no financial relationships that require disclosure.